Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cellular based immunotherapy for primary liver cancer
Yuanyuan Zheng, Yan Li, Jiao Feng, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 22

Showing 22 citing articles:

CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment
Jiachen Wen, Siyuan Wang, Rongxian Guo, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114884-114884
Closed Access | Times Cited: 78
Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges
Theodoros Pettas, Sofia Lachanoudi, Filippos F. Karageorgos, et al.
World Journal of Transplantation (2025) Vol. 15, Iss. 2
Closed Access | Times Cited: 1
circHMGCS1–016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma
Yaping Xu, Ze-Ning Dong, Siwei Wang, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 42
Nanodrug Delivery Systems in Antitumor Immunotherapy
Zishuo Guo, Jinhong Ye, Xuehao Cheng, et al.
Biomaterials Research (2024) Vol. 28
Open Access | Times Cited: 7
Therapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms
Jinhong Guo, Wenjie Yan, Hao Duan, et al.
Nutrients (2024) Vol. 16, Iss. 11, pp. 1642-1642
Open Access | Times Cited: 6
Research progress in nano-drug delivery systems based on the characteristics of the liver cancer microenvironment
Shijia Lu, Chenxiao Zhang, Jinglong Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 116059-116059
Open Access | Times Cited: 15
Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors
Jiawei Fan, Jianshu Zhu, He Zhu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 198, pp. 104362-104362
Open Access | Times Cited: 5
Molecular dynamics simulation based prediction of T-cell epitopes for the production of effector molecules for liver cancer immunotherapy
Sidra Zafar, Yuhe Bai, Syed Aun Muhammad, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0309049-e0309049
Open Access
Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview
Jingjing Li, Xuan-Fu Xu
International Journal of General Medicine (2023) Vol. Volume 16, pp. 1527-1540
Open Access | Times Cited: 10
Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma
Yue Li, Du He, Zi-Jian Lu, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize
Mirosław Janowski, A Andrzejewska
Molecular Therapy — Nucleic Acids (2022) Vol. 29, pp. 272-284
Open Access | Times Cited: 10
Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances
Dan Li, Shaoli Lin, Jessica Hong, et al.
Advances in cancer research (2022), pp. 415-449
Closed Access | Times Cited: 8
Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway.
Yu Liang, Ting Li, Heng Zhang, et al.
PubMed (2023) Vol. 15, Iss. 7, pp. 4521-4532
Closed Access | Times Cited: 4
Pyroptosis-related genes features on prediction of the prognosis in liver cancer: an integrated analysis of bulk and single-cell RNA sequencing
Zhihao Zhang, Feng Liu, Xin Lan, et al.
Heliyon (2024) Vol. 10, Iss. 19, pp. e38438-e38438
Open Access | Times Cited: 1
Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway
Li Xiao, Mengna Cui, Long Xu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma
Lingyun Wu, Xin Yin, Kan Jiang, et al.
Cancer Medicine (2022) Vol. 11, Iss. 7, pp. 1712-1731
Open Access | Times Cited: 7
The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network
Camilla Volponi, Aurora Gazzillo, Eduardo Bonavita
Cancers (2022) Vol. 14, Iss. 24, pp. 6151-6151
Open Access | Times Cited: 7
The Complement System: A Potential Therapeutic Target in Liver Cancer
Meng Yuan, Li Liu, Chenlin Wang, et al.
Life (2022) Vol. 12, Iss. 10, pp. 1532-1532
Open Access | Times Cited: 6
Temperature-responsive hydrogel for tumor embolization therapy
Xue- Er Hu, Yu-Rou Shi, Xun Zhu, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 80, pp. 104107-104107
Open Access | Times Cited: 5
Comprehensive characterization of Fidgetin on tumor immune microenvironment evaluation and immunotherapy in human hepatocellular carcinoma
Longju Qi, Shiyuan Chen, Zehua Liao, et al.
Aging (2024)
Open Access
The Risk Signature of Pyroptosis-Related Long Noncoding RNAs Predicts Prognosis and Indicates Immunotherapeutic Efficiency in Hepatocellular carcinoma
Wenjie Zhang, Xu Chen, Qiang Meng, et al.
Research Square (Research Square) (2024)
Open Access
A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma
Zhiyi Han, Tao Li, Heng Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access
Page 1

Scroll to top